Ironwood Pharmaceuticals Q4 FY2022 Investor Update

Ironwood Pharmaceuticals Q4 and full-year 2022 investor update presented February 16, 2023, covering financial results, LINZESS commercial performance, and pipeline progress including linaclotide pediatric indications, CNP-104 for PBC, and IW-3300 development programs.